Published online before print September 20, 2004, doi: 10.1161/01.CIR.0000143159.30585.90
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;110:1731-1737.)
© 2004 American Heart Association, Inc.
Arrhythmia/Electrophysiology |
Efficacy of Quinidine in High-Risk Patients With Brugada Syndrome
From the Department of Cardiology, Tel-Aviv Sourasky Medical Center, and Tel-Aviv University, Sackler School of Medicine, Tel-Aviv, Israel.
Correspondence to Bernard Belhassen, MD, Department of Cardiology, Tel-Aviv Sourasky Medical Center, Weizman St 6, Tel-Aviv 64239 Israel. E-mail bblhass{at}tasmc.health.gov.il
Received January 25, 2004; de novo received March 12, 2004; accepted May 20, 2004.
Background— Automatic implantable cardioverter-defibrillator therapy is considered the only effective treatment for high-risk patients with Brugada syndrome. Quinidine depresses Ito current, which may play an important role in the arrhythmogenesis of this disease.
Methods and Results— The effects of quinidine bisulfate (mean dose, 1483±240 mg) on the prevention of inducible and spontaneous ventricular fibrillation (VF) were prospectively evaluated in 25 patients (24 men, 1 woman; age, 19 to 80 years) with Brugada syndrome. There were 15 symptomatic patients (including 7 cardiac arrest survivors and 7 patients with unexplained syncope) and 10 asymptomatic patients. All 25 patients had inducible VF at baseline electrophysiological study. Quinidine prevented VF induction in 22 of the 25 patients (88%). After a follow-up period of 6 months to 22.2 years, all patients are alive. Nineteen patients were treated with quinidine for 6 to 219 months (mean±SD, 56±67 months). None had an arrhythmic event, although 2 had non–arrhythmia-related syncope. Administration of quinidine was associated with a 36% incidence of side effects that resolved after drug discontinuation.
Conclusions— Quinidine effectively prevents VF induction in patients with Brugada syndrome. Our data suggest that quinidine also suppresses spontaneous arrhythmias and could prove to be a safe alternative to automatic implantable cardioverter-defibrillator therapy for a substantial proportion of patients with Brugada syndrome. Randomized studies comparing these two therapies seem warranted.
Key Words: antiarrhythmic agents • electrophysiology • tachyarrhythmias
This article has been cited by other articles:
 |
|
 |
|
  K. Kyriazis, E. Bahlmann, H. van der Schalk, and K.-H. Kuck Electrical storm in Brugada syndrome successfully treated with orciprenaline; effect of low-dose quinidine on the electrocardiogram Europace, May 1, 2009; 11(5): 665 - 666. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Giustetto, S. Drago, P. G. Demarchi, P. Dalmasso, F. Bianchi, A. S. Masi, P. Carvalho, E. Occhetta, G. Rossetti, R. Riccardi, et al. Risk stratification of the patients with Brugada type electrocardiogram: a community-based prospective study Europace, April 1, 2009; 11(4): 507 - 513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Ehrlich Arrhythmogenic Brugada syndrome substrate: a proof of principle Cardiovasc Res, March 1, 2009; 81(4): 635 - 636. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Haissaguerre, F. Sacher, A. Nogami, N. Komiya, A. Bernard, V. Probst, S. Yli-Mayry, P. Defaye, Y. Aizawa, R. Frank, et al. Characteristics of recurrent ventricular fibrillation associated with inferolateral early repolarization role of drug therapy. J. Am. Coll. Cardiol., February 17, 2009; 53(7): 612 - 619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Viskin Idiopathic Ventricular Fibrillation "Le Syndrome d'Haissaguerre" and the Fear of J Waves. J. Am. Coll. Cardiol., February 17, 2009; 53(7): 620 - 622. [Full Text] [PDF]
|
|
|
|
|
|
D. Erkapic, T. Neumann, J. Schmitt, J. Sperzel, A. Berkowitsch, M. Kuniss, C. W. Hamm, and H.-F. Pitschner Electrical storm in a patient with arrhythmogenic right ventricular cardiomyopathy and SCN5A mutation Europace, July 1, 2008; 10(7): 884 - 887. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-S. Chen and S. G. Priori The Brugada Syndrome J. Am. Coll. Cardiol., March 25, 2008; 51(12): 1176 - 1180. [Full Text] [PDF]
|
|
|
|
|
|
S. Viskin, C. Antzelevitch, M. F. Marquez, and B. Belhassen Quinidine: a valuable medication joins the list of 'endangered species' Europace, December 1, 2007; 9(12): 1105 - 1106. [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Lehnart, M. J. Ackerman, D. W. Benson Jr, R. Brugada, C. E. Clancy, J. K. Donahue, A. L. George Jr, A. O. Grant, S. C. Groft, C. T. January, et al. Inherited Arrhythmias: A National Heart, Lung, and Blood Institute and Office of Rare Diseases Workshop Consensus Report About the Diagnosis, Phenotyping, Molecular Mechanisms, and Therapeutic Approaches for Primary Cardiomyopathies of Gene Mutations Affecting Ion Channel Function Circulation, November 13, 2007; 116(20): 2325 - 2345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Paul, J. Gerss, E. Schulze-Bahr, T. Wichter, C. Vahlhaus, A. A.M. Wilde, G. Breithardt, and L. Eckardt Role of programmed ventricular stimulation in patients with Brugada syndrome: a meta-analysis of worldwide published data Eur. Heart J., September 1, 2007; 28(17): 2126 - 2133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Viskin and O. Rogowski Asymptomatic Brugada syndrome: a cardiac ticking time-bomb? Europace, September 1, 2007; 9(9): 707 - 710. [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. Stokoe, R. Balasubramaniam, C. A. Goddard, W. H. Colledge, A. A. Grace, and C. L.-H. Huang Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/ murine hearts modelling the Brugada syndrome J. Physiol., May 15, 2007; 581(1): 255 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Viskin Brugada Syndrome in Children: Don't Ask, Don't Tell? Circulation, April 17, 2007; 115(15): 1970 - 1972. [Full Text] [PDF]
|
|
|
|
|
|
V. Probst, I. Denjoy, P. G. Meregalli, J.-C. Amirault, F. Sacher, J. Mansourati, D. Babuty, E. Villain, J. Victor, J.-J. Schott, et al. Clinical Aspects and Prognosis of Brugada Syndrome in Children Circulation, April 17, 2007; 115(15): 2042 - 2048. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Antzelevitch, G. D. Pollevick, J. M. Cordeiro, O. Casis, M. C. Sanguinetti, Y. Aizawa, A. Guerchicoff, R. Pfeiffer, A. Oliva, B. Wollnik, et al. Loss-of-Function Mutations in the Cardiac Calcium Channel Underlie a New Clinical Entity Characterized by ST-Segment Elevation, Short QT Intervals, and Sudden Cardiac Death Circulation, January 30, 2007; 115(4): 442 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S. Stokoe, G. Thomas, C. A. Goddard, W. H. Colledge, A. A. Grace, and C. L.-H. Huang Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/{Delta} murine hearts modelling long QT syndrome 3 J. Physiol., January 1, 2007; 578(1): 69 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Developed in Collaboration With the European Heart, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) J. Am. Coll. Cardiol., September 5, 2006; 48(5): e247 - e346. [Full Text] [PDF]
|
|
|
|
|
|
Writing Committee Members, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Europace, September 1, 2006; 8(9): 746 - 837. [Full Text] [PDF]
|
|
|
|
|
|
A. Watanabe, K. Fukushima Kusano, H. Morita, D. Miura, W. Sumida, S. Hiramatsu, K. Banba, N. Nishii, S. Nagase, K. Nakamura, et al. Low-dose isoproterenol for repetitive ventricular arrhythmia in patients with Brugada syndrome Eur. Heart J., July 1, 2006; 27(13): 1579 - 1583. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Meregalli, A. A.M. Wilde, and H. L. Tan Pathophysiological mechanisms of Brugada syndrome: Depolarization disorder, repolarization disorder, or more? Cardiovasc Res, August 15, 2005; 67(3): 367 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Brugada, R. Brugada, J. Brugada, S. G. Priori, C. Napolitano, P. Brugada, R. Brugada, J. Brugada, S. G. Priori, and C. Napolitano Should patients with an asymptomatic Brugada electrocardiogram undergo pharmacological and electrophysiological testing? Circulation, July 12, 2005; 112(2): 279 - 292. [Full Text] [PDF]
|
|
|
|
|
|
M. M. Scheinman and E. Keung The year in clinical electrophysiology J. Am. Coll. Cardiol., March 1, 2005; 45(5): 790 - 795. [Full Text] [PDF]
|
|
|
|
|
|
L. Eckardt, V. Probst, J. P.P. Smits, E. S. Bahr, C. Wolpert, R. Schimpf, T. Wichter, P. Boisseau, A. Heinecke, G. Breithardt, et al. Long-Term Prognosis of Individuals With Right Precordial ST-Segment-Elevation Brugada Syndrome Circulation, January 25, 2005; 111(3): 257 - 263. [Abstract] [Full Text] [PDF]
|
|